Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

NCT03891862 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT03891862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03891862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 4
Overall status
Completed
Start date
March 18, 2019
Completion date
January 30, 2020
Enrollment
135 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

tardive dyskinesia (td)